Major Pharmaceuticals has recalled 12 levothyroxine sodium tablet products distributed nationwide after the FDA classified the action as a Class II recall because the medications were subpotent, according to a July 28 FDA enforcement report. The recall was initiated July 13 and classified July 17.
Subpotent drugs contain less active ingredient than specified on the label, which can reduce the medication’s intended effect. The recalled products include levothyroxine sodium tablets in 25 micrograms, 50 micrograms, 75 micrograms, 88 micrograms, 112 micrograms, 125 micrograms and 150 micrograms strengths packaged in 100-tablet and 10-tablet unit-dose blister cartons. The affected lots have expiration dates ranging from July 2026 through January 2027.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.